These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 39205268

  • 21. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC, Medinger M, Halter JP, Baldomero H, Hirsch HH, Tzankov A, Dirnhofer S, Passweg JR, Tichelli A.
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [Abstract] [Full Text] [Related]

  • 22. Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.
    Ratiu C, Dufresne SF, Thiant S, Roy J.
    Curr Oncol; 2024 May 14; 31(5):2780-2795. PubMed ID: 38785492
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ.
    Blood; 2002 Jun 15; 99(12):4364-9. PubMed ID: 12036863
    [Abstract] [Full Text] [Related]

  • 25. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
    Chen J, Sun YQ, Xu LP, Zhang XH, Liu KY, Mo XD, Cheng YF, Huang XJ, Wang Y.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr 14; 44(4):284-288. PubMed ID: 37356996
    [Abstract] [Full Text] [Related]

  • 26. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.
    Rouce RH, Louis CU, Heslop HE.
    Curr Opin Hematol; 2014 Nov 14; 21(6):476-81. PubMed ID: 25159713
    [Abstract] [Full Text] [Related]

  • 27. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M, Ito A, Maeshima AM, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T.
    Int J Hematol; 2020 Aug 14; 112(2):193-199. PubMed ID: 32472530
    [Abstract] [Full Text] [Related]

  • 28. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.
    J Clin Virol; 2012 Mar 14; 53(3):186-94. PubMed ID: 22182950
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A, Hallböök H, Arvidson J, Sällström K, Bondeson K, Pauksens K.
    Leuk Lymphoma; 2018 May 14; 59(5):1172-1179. PubMed ID: 28831836
    [Abstract] [Full Text] [Related]

  • 31. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu L, Zhang X, Feng S.
    Biol Blood Marrow Transplant; 2018 Jul 14; 24(7):1341-1349. PubMed ID: 29530767
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY, Zhao SS, Wang XK, Wang L, Wang FY, Fang S, Liu ZX, Guan LX, Liu YC, Ding Y, Dou LP, Wang LL, Gao CJ.
    Ann Transplant; 2019 Apr 03; 24():175-184. PubMed ID: 30940797
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G, Geromin A, Cerno M, Savignano C, Rinaldi C, Barbone F, Fanin R.
    Transpl Infect Dis; 2013 Jun 03; 15(3):259-67. PubMed ID: 23405972
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.
    Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM.
    Front Immunol; 2019 Jun 03; 10():2489. PubMed ID: 31736946
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.